Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study
Authors' conclusion
Our study suggested the progression of osteoporosis in RA patients during b/tsDMARDs treatment without anti-OP. BTMs may not reflect BMD change.
Study context
- Population
- Rheumatoid arthritis (RA) patients enrolled at the time of first b/tsDMARD administration
- Participants
- 1,164 patients
- Exposure
- Anti-OP at baseline vs no anti-OP at baseline (no history of fracture), during b/tsDMARD treatment
- Outcome
- Differences in changes in BMD according to b/tsDMARD type, and correlation between BMD and BTMs
- Follow-up
- 52 weeks
Methodological detailsmulticentre, observational, real-world cohort
- Multicentre
- Observational
- Real-world cohort
Main finding
As reported in the abstract
BMD change (femoral neck F, radial R; g/cm³) · weeks 0/26/52
- No anti-OP: femoral neck bone mineral density (BMD), mean, baseline to week 26 (significant decrease)
- 0.666-0.655
- No anti-OP: radial BMD, baseline to week 26 (significant decrease)
- 0.518-0.514
- No anti-OP: femoral neck BMD at week 52 (continued decline)
- 0.653
- No anti-OP: radial BMD at week 52
- 0.509
- Anti-OP: femoral neck BMD, weeks 0/26/52 (stable)
- 0.551/0.551/0.555
- Anti-OP: radial BMD, weeks 0/26/52 (stable)
- 0.415/0.416/0.415
Observational data: associations, not effects.
Further findings
RA disease activity (CDAI), mean · baseline to week 26; weeks 26-52
- Mean CDAI baseline to week 26
- 25.5 to 4.5
- CDAI during weeks 26-52
- 5.3-4.4
Original publication
Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. Rheumatology (Oxford). Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →